Severe ARDS due to Ruxolitinib discontinuation syndrome: case presentation and literature review

OBJECTIVE: Discontinuation of Ruxolitinib (RUX), a JAK1/JAK2 inhibitor, can induce symptom-relapse and even life-threatening adverse events. Due to increasing use of RUX, this so-called RUX discontinuation syndrome (RDS) is becoming more prevalent. To create better awareness for this potentially fat...

Descripción completa

Detalles Bibliográficos
Autores principales: Houthuys, Jona F., Wilmer, Alexander P., Peetermans, Marijke, Meersseman, Philippe, Devos, Timothy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9720527/
https://www.ncbi.nlm.nih.gov/pubmed/36478803
http://dx.doi.org/10.1016/j.heliyon.2022.e11782

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9720527/
https://www.ncbi.nlm.nih.gov/pubmed/36478803
http://dx.doi.org/10.1016/j.heliyon.2022.e11782

Ejemplares similares